Biotech

All Articles

AC Immune sees 'site' prospective in Alzheimer's drug information

.After much more than twenty years of work with neurodegenerative health conditions, Swiss biotech a...

GSK drops ph. 2 HPV vaccine over shortage of best-in-class prospective

.GSK has actually junked a period 2 human papillomavirus (HPV) injection from its pipe after decidin...

OS Therapies refiles $6M IPO to fund HER2 medication, preclinical ADCs

.Operating system Therapies are going to provide on the NYSE American inventory swap this morning vi...

ALX's waning CD47 response rate sends out supply spiraling down

.ALX Oncology's phase 2 stomach cancer response price has actually compromised. After finding its ow...

Ionis axes eye condition coming from aim ats of Roche-partnered possibility after data disappoint

.Another of Ionis Pharmaceuticals' crucial midphase readouts has actually disappointed expectations,...

Biogen's chief executive officer pointed out no high-risk deals in 2023. He prepares to become daring

.While Biogen's pharma peers are seeking for late-stage properties with little bit of danger, chief ...

Instil refills pipe in $2B biobucks deal with ImmunOnco

.Instil Biography has actually been a biotech looking for a pipe after it scrapped its lead possessi...

Biogen ignores Denali Alzheimer's collab

.Biogen has actually handed back legal rights to an early Alzheimer's illness plan to Denali Therapi...

Takeda touches brand-new head people oncology organization-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of substantial leadership hirings, shootings...

Vertex, beaten by AATD again, goes down 2 resources on throw away heap

.Tip's effort to address a rare hereditary condition has actually reached an additional setback. The...